GICS Sector : Healthcare
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States.The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses.It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update
Nov -14
AWH Announces Third Quarter 2025 Financial Results
Nov -10
Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston
Oct -29
AWH to Hold Third Quarter 2025 Earnings Conference Call on Monday, November 10, 2025
Oct -20
AWH Closes $9.3 Million Mortgage Financing on Three Ohio Properties
Sep -30
Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
Sep -18
Aspira Women's Health Appoints New Chief Financial Officer
Sep -04
Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update
Aug -13
Aspira Women's Health Inc.'s bio-analytic and diagnostic services growth of 10.33% is driven by increasing demand for non-invasive prenatal testing, rising awareness of women's health issues, and advancements in genetic testing technology. Additionally, growing adoption of precision medicine and personalized healthcare are contributing to the segment's growth.
A non-invasive, blood-based test for ovarian cancer detection
A comprehensive panel of biomarkers for ovarian cancer risk assessment
A non-invasive, blood-based test for endometriosis diagnosis
A non-invasive, blood-based test for uterine fibroids diagnosis
A personalized reproductive health planning tool
Aspira Women's Health Inc. operates in a niche market, providing women's health and wellness services. While there are substitutes available, they are not easily accessible, and the company's unique offerings mitigate the threat of substitutes.
Aspira Women's Health Inc. has a strong brand reputation and provides specialized services, giving customers limited bargaining power. The company's focus on women's health and wellness also creates a loyal customer base.
Aspira Women's Health Inc. relies on a network of suppliers for medical equipment, disposables, and other essential items. While the company has some bargaining power, suppliers also have some leverage, particularly for specialized equipment.
Entering the women's health and wellness market requires significant investment in infrastructure, technology, and talent. Aspira Women's Health Inc. has a strong brand and established relationships, making it difficult for new entrants to gain traction.
The women's health and wellness market is highly competitive, with multiple players vying for market share. Aspira Women's Health Inc. faces intense competition from established players and new entrants, requiring continuous innovation and differentiation to maintain its market position.
| Value | |
|---|---|
| Debt Weight | 4041.67% |
| Debt Cost | 3.95% |
| Equity Weight | -3941.67% |
| Equity Cost | 11.81% |
| WACC | -305.84% |
| Leverage | -102.54% |
Value: 7.2
Growth: 4.0
Quality: 3.5
Yield: 0.0
Momentum: 10.0
Volatility: 1.7
1-Year Total Return ->
Value: 7.1
Growth: 1.7
Quality: 4.1
Yield: 2.0
Momentum: 7.0
Volatility: 3.3
1-Year Total Return ->
Value: 5.0
Growth: 7.9
Quality: 8.1
Yield: 0.0
Momentum: 1.0
Volatility: 1.7
1-Year Total Return ->
Value: 9.8
Growth: 4.7
Quality: 5.6
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->
Value: 7.8
Growth: 3.6
Quality: 4.3
Yield: 0.0
Momentum: 1.5
Volatility: 1.3
1-Year Total Return ->
Value: 9.4
Growth: 0.9
Quality: 4.3
Yield: 0.0
Momentum: 1.0
Volatility: 0.0
1-Year Total Return ->